KOL Insight

Chronic Heart Failure KOL Interview – US, Midwest

This interview with a US-based key opinion leader (KOL) provides insights into patient segmentation, as well as prescribing trends for key marketed brands and late-phase pipeline therapies for chronic heart failure (CHF). Marketed brands discussed include Entresto, Farxiga, Jardiance, Corlanor, and Verquvo, while pipeline therapies highlighted are Furoscix, Invokana, Kerendia, omecamtiv mecarbil, Revascor, and Zynquista.